Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 10 November 2023, including: US approval for Eli Lilly and Company’s obesity drug; a look at the future of the obesity market; Bristol Myers Squibb Company’s ADC deal; Roche Holding AG’s MS plans; and one Chinese firm’s CAR-T plans.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Plans ‘Big, Bold’ Launch For Zepbound" - Scrip, 8 Nov, 2023.)
(Also see "The Next Frontier In Obesity: Better, Not More, Weight Loss" - Scrip, 6 Nov, 2023.)
(Also see "BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader" - Scrip, 7 Nov, 2023.)
(Also see "How Roche Plans To Stay Ahead In MS And Catch Up In Alzheimer’s" - Scrip, 3 Nov, 2023.)
(Also see "China CEO Interview: Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery" - Scrip, 6 Nov, 2023.)